-
EHA 2026 Echoes | Qian Jiang: Addressing Both Ends of the CML Spectrum—Advancing Precision Therapy and the New Era of Treatment-Free Remission
At the 2026 Congress of the European Hematology Association (EHA 2026), the team led by Professor Qian Jiang from Peking University People’s Hospital presented several important studies addressing key challenges in chronic myeloid leukemia (CML), including the biological heterogeneity of accelerated-phase disease and predictors of treatment-free remission (TFR).
-
EHA 2026 Echoes | Ruijuan Sun and Hai He: Allogeneic HSCT Overcomes the Poor Prognosis Associated with NUP98::NSD1-Positive Acute Myeloid Leukemia
The 2026 Congress of the European Hematology Association (EHA 2026) was held from June 11 to 14 in Stockholm, Sweden. As one of the most influential international meetings in hematology, EHA brings together leading experts from around the world to showcase the latest advances in basic science, translational research, and clinical practice.
-
EHA 2026 | Six Studies from Professor Jin Lu’s Team Selected for Presentation, Including Two Oral Presentations Showcasing China’s Growing Impact in Hematology
As the 2026 Congress of the European Hematology Association (EHA 2026) prepares to open in Stockholm, Sweden, the global hematology community is once again gathering to share the latest scientific advances and shape the future of blood disease research and treatment.
-
CGOG 2026 Day 1 Highlights | ASCO Gastric Cancer Updates Session
On June 9, 2026, the 16th Annual Meeting of the Chinese Gastrointestinal Oncology Cooperative Group (CGOG) officially commenced. The conference runs from June 9 to June 13 and features a series of dedicated sessions highlighting the latest advances in gastrointestinal oncology.
-
CGOG 2026 Day 1 Highlights | ASCO Esophageal Cancer Updates Session
On June 9, 2026, the 16th Peking University Gastrointestinal Oncology Forum and CGOG Annual Meeting officially opened. The first day featured three dedicated ASCO Highlights sessions showcasing the latest advances in gastrointestinal oncology.
-
CGOG 2026 Day 1 Highlights | ASCO Rare Tumors and Rare Mutations Updates Session
On June 9, the 2026 Peking University Gastrointestinal Oncology Forum and the 16th CGOG Annual Meeting officially commenced. On the opening day, three dedicated ASCO Highlights sessions showcased the latest advances from the global oncology community. Among them, the ASCO Rare Tumors and Rare Mutations Updates Session attracted more than 19,000 online viewers.
-
ASCO Voices from China | Lijuan Chen: A Novel Highly Selective HDAC Inhibitor–Based Triplet Regimen Offers a New Strategy for Relapsed/Refractory Multiple Myeloma
The rapid emergence of CAR-T cell therapies and bispecific antibodies has transformed the treatment landscape for relapsed/refractory multiple myeloma (RRMM), leading to substantial improvements in patient outcomes. However, limitations related to accessibility, treatment costs, manufacturing complexity, and toxicity management continue to restrict their widespread use. As a result, there remains a pressing need for innovative…
-
ASCO 2026 Voices from China | Haiwen Huang: New Frontiers in Frontline Lymphoma Optimization and Precision Treatment for Special Patient Populations
As part of its special ASCO 2026 coverage series, “China Perspectives at ASCO,” Oncology Frontier – Hematology Frontier invited leading Chinese experts to interpret the most practice-changing research presented at this year’s meeting and discuss its relevance to clinical practice in China.
Connecting Medical Expertise through Media